Abiopharma

🔍 OFFER DAVID SCOTT (Executive)

Company: FLEX LTD. (FLEX)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 43,724 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: A | equity_swap_involved: 0 | shares_owned_after: 97,138.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,479 shares of Ordinary Shares at $138.6103 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 95,659.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 1,882 shares of Ordinary Shares at $139.635 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 93,777.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 2,767 shares of Ordinary Shares at $140.596 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 91,010.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 1,453 shares of Ordinary Shares at $141.5232 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 89,557.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 5,952 shares of Ordinary Shares at $142.9593 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 83,605.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Sold 7,102 shares of Ordinary Shares at $143.8863 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 76,503.00 | transaction_form_type: 4 | Footnotes: F2, F8
• Sold 1,577 shares of Ordinary Shares at $144.479 per share (Direct)
  Date: 2026-05-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 74,926.00 | transaction_form_type: 4 | Footnotes: F2, F9, F10
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-05-08 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 106,471.00

Footnotes:

• F1: On June 14, 2023, the Reporting Person was awarded performance-based restricted share units ("PSUs") within a preset range, with the actual number contingent upon the achievement of a certain performance criterion with respect to the three-year performance period ending on March 31, 2026. The Issuer certified the achievement of the performance criterion, and the PSUs fully vested, on May 8, 2026, and were subject to applicable taxes upon delivery.
• F2: The sales reported in this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs.
• F3: Price reflects weighted average sales price; actual sales prices ranged from $138.11 to $139.093. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F4: Price reflects weighted average sales price; actual sales prices ranged from $139.11 to $140.09. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F5: Price reflects weighted average sales price; actual sales prices ranged from $140.12 to $141.11. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F6: Price reflects weighted average sales price; actual sales prices ranged from $141.131 to $142.125. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F7: Price reflects weighted average sales price; actual sales prices ranged from $142.354 to $143.33. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F8: Price reflects weighted average sales price; actual sales prices ranged from $143.357 to $144.355. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F9: Price reflects weighted average purchase price; actual purchase prices ranged from $144.36 to $144.77. The Reporting Person undertakes to provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased or sold at each separate price.
• F10: Includes the following: (1) 18,768 unvested restricted share units ("RSUs"), which will vest in two equal annual installments beginning on June 12, 2026; (2) 20,071 unvested RSUs, which will vest in three equal annual installments beginning on June 12, 2026; and (3) 14,574 unvested RSUs, which will vest on June 14, 2026.
• F11: Each unvested RSU represents a contingent right to receive one unrestricted, fully transferable share for each vested RSU which has not been previously forfeited.